Tandon 2006.

Methods	Allocation: random. Blindness: open label. Duration: 8 weeks. Design: prospective, parallel group. Location: multicentric in USA.
Participants	Diagnosis: Schizophrenia or schizoaffective disorder (DSM IV), required initiation of antipsychotics, antipsychotic switch clinically appropriate. N = 1599. Age: 18‐75 years. History: duration of illness not reported, age at onset not reported. Setting: Outpatients.
Interventions	1. Aripiprazole: 10 mg‐30 mg/day (mean 19.9 mg/day); N = 1295. 2. Other antipsychotic: recommended dose; N = 304.
Outcomes	Global state: CGI‐I. Adverse effects: At least one adverse effect, extrapyramidal adverse effects, gastrointestinal disorders, sleep disturbances. Others: POM.
Notes	Primary goal was evaluating the effectiveness of aripiprazole in general psychiatric outpatient practice setting. The other antipsychotic treatment group was primarily included for interpreting the safety data and not for direct comparison. Unable to use data from CGI‐I and POM.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	4:1 computer‐generated randomised schedule using Interactive Voice Response System.
Allocation concealment (selection bias)	High risk	Open label.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open label.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	LOCF method used to account for people leaving the study early.
Selective reporting (reporting bias)	High risk	Adverse events were reported if they were > 5%. Scales if used were not reported.
Other bias	High risk	Industry sponsored.